Leiden, the Netherlands, February 7, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the ...

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, ...

Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full ...

The average one-year price target for Pharming Group N.V. - Depositary Receipt (NasdaqGM:PHAR) has been revised to $19.77 / ...

Leiden, the Netherlands, February 20, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the ...

CSL Behring and Pharming have mutually agreed that CSL will dismiss Pharming from the case against Dr. Chiao Pharming's dismissal did not involve any fault, liability, or penalties against Pharming ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pharming (NASDAQ:PHAR) in the last three months. The following table provides a quick overview ...

Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to ...

When we look around, we are amazed at the speed with which the world is changing. Online fraud techniques such as Pharming and other cybercrime attacks are at an all-time high. To overcome such ...

Leiden, The Netherlands, October 13, 2008. Biotech companyPharmingGroup NV ("Pharming" or "The Company") (Euronext: PHARM)announcedtoday the appointment of Dr Sijmen de Vries as ChiefExecutiveOfficer ...